Kanzius Cancer Research Foundation (KCRF) announces research conducted in the Kanzius/Curley Lab at The University of Texas MD Anderson Cancer Centre has been published in the December 2010 issue of the American Association of Cancer Research’s Clinical Cancer Research journal. The manuscript illustrates how Drs Steven A. Curley and Evan S. Glazer’s studies prove that radiofrequency fields can treat pancreatic tumours, which today, kill more than 95% of diagnosed patients. Studies found that non-invasive radiofrequency (RF) fields were effective in controlling relatively large pancreatic cancer cells. Additionally, this process took place without any injury to surrounding tissue or changes in subject behaviour.

The manuscript describes the process as subjects are exposed to 10 minutes of non-ionizing radiofrequency (RF) radiation followed by 36 hours of treatment using targeted gold nanoparticles (AuNP). This revolutionary design shows that the Kanzius RF machine alongside these particular nanoparticles create an effective formula for controlling pancreatic cancer cells.

“John Kanzius, who created the RF device, once envisioned a cancer treatment that would be both effective and have zero side effects,” remarked Curley, Chief of Gastrointestinal Tumour Surgery and Programme Director of Multidisciplinary Gastrointestinal Cancer Care at The University of Texas MD Anderson Cancer Centre. “These experiments demonstrate that the Kanzius RF device controls pancreatic cancer cells without any damage to nearby cells, or normal tissues and organs. We still have a lot of work to do but this is an important proof of principle.”

“Every day, our team at the Kanzius Cancer Research Foundation works to help fund this incredible research” said Mark Neidig, executive director of KCRF. “These recent findings bring us one step closer to our goal of producing an effective, non-invasive cancer treatment that doesn’t have the side effects associated with current treatments like chemotherapy and radiation.”

This manuscript “Non-invasive Radiofrequency Field Destruction of Pancreatic Andenocarcinoma Xenografts Treated with Targeted Gold Nanoparticles” can be found in the December 2010 issue of the American Association of Cancer Research.